Literature DB >> 26596011

[Clinical effect on the treatment of the low-middle frequency sudden hearing loss with postaurical injection of methylprednisolone].

Sien Wu, Qingming Li, Suhong Huang.   

Abstract

OBJECTIVE: To evaluate the clinical efficacy on the treatment of the low-middle frequency sudden hearing loss with postaurical injection of methylprednisolone.
METHOD: The 80 cases of the low-middle frequency sudden hearing loss were randomly divided into postaurical injection and oral hormone groups. The postaurical injection group (42 cases) received the postaurical injection of methylprednisolone, 40 mg/2 d, combined with the treatment of Ginkgo dipyidamolum and Alprostadil for 14 d; The oral hormone group (38 cases) received the oral prednisone, 1 mg/kg/d, administrated once on the morning for 3 d, if effective, prolonging for another 2 d, as mentioned above for Ginkgo dipyidamolum and Alprostadil. RESULT: The total effective rate was 88.10% in postaurical injection group and 86. 4o%in oral hormone group. There was no significant difference between the twbogroups( P> 0. 5).
CONCLUSION: Postaurical injection of methylprednisolone for the low-middle frequency sudden hearing loss is effective, safe and simple, which may be an alternative for systemic administration of gulcocorticoid.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26596011

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 2096-7993


  2 in total

1.  Postaurical injection is a systemic delivery supported by symmetric distribution of Gd-DOTA in both the ipsilateral and contralateral ears.

Authors:  Jing Zou
Journal:  J Otol       Date:  2016-01-29

2.  Postauricular injection glucocorticoid in the treatment of sudden hearing loss: A protocol for systematic review and meta-analysis.

Authors:  Jiao Liang; Hui Xie; Han-Jen Chiang; Sha Li; Zhiqing Liu; Jiongke Li; Chenyi Zeng
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.